By Julian Pecquet - 02/23/12 02:59 PM EST
The agency transmitted its agreement with industry to Congress in January. Lawmakers introduced bipartisan legislation this month calling on generic drugmakers to pay about $1.5 billion over the next five years to help fund the federal regulators who review and approve new drugs.
Hamburg also said her agency was close to announcing a new director of the Office of Generic Drugs, which she said she had hoped to announce at the conference. The previous director, Gary Buehler, was removed from the post in March 2010 after Hamburg lamented an "unprecedented spike" in the applications backlog during a speech at the GpHA's 2010 conference.